277 related articles for article (PubMed ID: 20226286)
1. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
[TBL] [Abstract][Full Text] [Related]
2. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
4. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
[TBL] [Abstract][Full Text] [Related]
6. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
[TBL] [Abstract][Full Text] [Related]
7. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
Genant HK; Libanati C; Engelke K; Zanchetta JR; Høiseth A; Yuen CK; Stonkus S; Bolognese MA; Franek E; Fuerst T; Radcliffe HS; McClung MR
Bone; 2013 Oct; 56(2):482-8. PubMed ID: 23871852
[TBL] [Abstract][Full Text] [Related]
8. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
11. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
Engelke K; Fuerst T; Dardzinski B; Kornak J; Ather S; Genant HK; de Papp A
J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller PD; Epstein S; Sedarati F; Reginster JY
Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
[TBL] [Abstract][Full Text] [Related]
13. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
14. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
Bock O; Börst H; Beller G; Armbrecht G; Degner C; Martus P; Roth HJ; Felsenberg D
Bone; 2012 Jan; 50(1):317-24. PubMed ID: 22067902
[TBL] [Abstract][Full Text] [Related]
15. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Reginster JY; Adami S; Lakatos P; Greenwald M; Stepan JJ; Silverman SL; Christiansen C; Rowell L; Mairon N; Bonvoisin B; Drezner MK; Emkey R; Felsenberg D; Cooper C; Delmas PD; Miller PD
Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
[TBL] [Abstract][Full Text] [Related]
17. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
[TBL] [Abstract][Full Text] [Related]
18. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
19. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
20. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
